Variational AI Partners with Merck in $349 Million AI Drug Discovery Collaboration
核心洞察
Variational AI (搜索) has entered a collaboration with Merck (搜索) to apply its Enki™ generative AI platform to discover and develop novel small molecule therapeutics against two undisclosed targets.
The agreement includes an upfront payment to Variational AI (搜索) with potential milestone payments totaling up to $349 million, while Merck (搜索) retains exclusive rights to develop and commercialize resulting compounds.
The collaboration will utilize a fine-tuned version of Enki™ trained on Merck (搜索)'s proprietary datasets to generate and optimize small molecule candidates with improved probability of success.
Variational AI (搜索), a Vancouver-based generative AI drug discovery company, has announced a significant collaboration with pharmaceutical giant Merck (搜索) to leverage artificial intelligence in the development of novel small molecule therapeutics. The partnership, announced on September 23, 2025, focuses on applying Variational AI's proprietary Enki™ platform to design and optimize compounds against two therapeutic targets designated by Merck.
Financial Terms and Structure
Under the collaboration agreement, Variational AI (搜索) will receive an upfront payment and is eligible for milestone payments with a total potential deal value reaching $349 million. Merck (搜索) will maintain exclusive rights to develop and commercialize any compounds arising from the partnership, positioning the pharmaceutical company to fully capitalize on successful discoveries.
The collaboration represents a strategic approach to drug discovery economics, with Variational AI (搜索) CEO Handol Kim noting that "this is a compelling framework that has the potential to significantly accelerate and redefine the unit economics of drug discovery."
Technology Integration
The partnership will utilize a fine-tuned version of Variational AI (搜索)'s Enki™ platform, specifically trained on Merck (搜索)'s proprietary datasets. This customized approach aims to create unique generative models with enhanced power and accuracy compared to standard applications.
"We are excited to apply our proprietary machine learning algorithms to Merck (搜索)'s extensive and valuable datasets to create unique, fine-tuned generative models of unprecedented power and accuracy," Kim explained.
Merck's AI Strategy
The collaboration aligns with Merck (搜索)'s broader initiative to integrate artificial intelligence into its drug discovery operations. Robert M. Garbaccio, Ph.D., Vice President and Head of Discovery Chemistry at Merck Research Laboratories, emphasized the company's commitment to leveraging AI technology.
"At Merck (搜索), we are working to harness the potential of AI to improve efficiency, speed, and quality of candidates earlier in the discovery continuum," Garbaccio stated. "We look forward to working with Variational AI (搜索) to apply their Enki™ platform to challenging therapeutic targets."
Platform Capabilities
Variational AI (搜索)'s Enki™ platform operates as a foundation model trained on the company's internal data, a curated version of all publicly available data, and proprietary generative models. The platform is designed to create and optimize small molecule leads based on partner target product profiles, with the goal of improving the probability of success in drug development.
The company's research has demonstrated the platform's efficiency, with AI-generated molecules outperforming conventional high-throughput screening methods. According to Variational AI (搜索)'s findings, 100 AI-generated molecules created by the Enki algorithm outperformed 1,000,000 molecules in conventional screening approaches.
Company Background
Founded by machine learning researchers from prestigious institutions including MIT, Caltech, Google Research, Microsoft Research, and D-Wave Quantum, Variational AI (搜索) has established itself as a specialized player in the generative AI drug discovery space. The venture-backed company has previously announced partnerships with other organizations, including co-development agreements with Oncocross (搜索) for chronic skin inflammation (搜索) treatments and collaborations with Rakovina Therapeutics (搜索) for brain-penetrant ATR inhibitor discovery.